Standard Bariatrics is a technology company.
Standard Bariatrics has raised $35.0M across 1 funding round.
Standard Bariatrics has raised $35.0M in total across 1 funding round.
Standard Bariatrics has raised $35.0M in total across 1 funding round.
Standard Bariatrics's investors include 4See Ventures, New Leaf Venture Partners, U.S. Venture Partners.
Standard Bariatrics, Inc. (SBI) is a Cincinnati-based medical device company that develops innovative surgical tools for obesity treatment, primarily through bariatric procedures like sleeve gastrectomy.[1][2][3] Its flagship product, the Titan SGS powered stapler, creates a consistent 23 cm continuous staple line for symmetrical gastric sleeve pouches in a single firing, reducing variability and improving patient outcomes for bariatric surgeons.[1][3] The company serves surgeons and healthcare providers treating obesity, addressing inconsistent sleeve anatomy from multi-firing staplers, with over 12,000 procedures performed using its technology and early sales hitting $1M by late 2021.[1][3] SBI has since been acquired by Teleflex Incorporated, integrating its portfolio—including the Standard Clamp—into a broader medical tech lineup, while securing GPO agreements like with Premier, Inc. to expand access.[3][4]
Founded in January 2014 in Cincinnati, Ohio, Standard Bariatrics emerged from a biodesign process targeting unmet needs in sleeve gastrectomy for obesity, one of medicine's most undertreated conditions.[2][3] The idea stemmed from innovators seeking to standardize pouch creation without new procedures or PMA regulatory hurdles, focusing on reimbursed bariatric techniques.[2] Key early milestones included Ben Thompson, the first CTO (now retired), prototyping a 300mm stapler in March 2015 and securing FDA clearance for the initial Standard Clamp—a reusable, articulating device—in May 2016.[2] Iterative refinements followed, simplifying designs for safety and reliability, leading to the Titan SGS's FDA clearance in April 2021 and first use in August 2021.[1][2] Backed by a team with over 175 years of medtech experience, the company achieved rapid traction, reaching $1M in Titan SGS sales by November 2021 across multiple U.S. states.[1]
Standard Bariatrics rides the surging demand for obesity treatments amid rising global rates, where bariatric surgery—especially sleeve gastrectomy—offers superior long-term results but faces challenges like procedural variability.[2][3] Timing aligns with FDA-cleared innovations lowering intervention thresholds and standardizing outcomes, countering market forces like high obesity prevalence and healthcare cost pressures.[1][2] By partnering with surgeons and now Teleflex—a leader in surgical and metabolic tech—SBI influences the ecosystem through expanded access, GPO contracts, and portfolio growth, shaping consistent bariatric standards and potentially broader metabolic surgery adoption.[3][4]
With Teleflex's resources, Standard Bariatrics is poised to scale Titan SGS globally, leveraging GPO expansions and its 12,000+ procedure base for deeper market penetration.[3][4] Trends like AI-enhanced medtech, value-based care, and obesity drug-surgery combos will amplify its role in hybrid treatments, evolving influence toward portfolio leadership in bariatrics. This positions SBI—from milestone hitter to Teleflex asset—as a cornerstone for repeatable obesity surgery outcomes.[1][3]
Standard Bariatrics has raised $35.0M across 1 funding round. Most recently, it raised $35.0M Series B in May 2021.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| May 1, 2021 | $35.0M Series B | 4See Ventures, New Leaf Venture Partners, U.S. Venture Partners |